Key result
Liver-specific overexpression of lipoprotein lipase in high-fat diet-fed mice significantly attenuated hepatic lipid accumulation and improved glucose tolerance and insulin resistance.
Why the study?
Hepatic lipid accumulation impairs insulin sensitivity and glucose metabolism, prompting investigation into whether suppressing hepatic lipid accumulation via LPL overexpression improves metabolism.
Does liver-specific overexpression of lipoprotein lipase attenuate hepatic lipid accumulation and improve glucose metabolism in high-fat diet-fed mice?
Does liver-specific overexpression of lipoprotein lipase attenuate hepatic lipid accumulation and improve glucose metabolism in high-fat diet-fed mice?
Answers are grounded in this paper and cite their sources.
Liver-specific overexpression of lipoprotein lipase in mice attenuates high-fat diet-induced hepatic lipid accumulation and improves insulin resistance, suggesting a potential therapeutic mechanism for metabolic syndromes.
The liver is the main organ that regulates lipid and glucose metabolism. Ectopic lipid accumulation in the liver impairs insulin sensitivity and glucose metabolism. Lipoprotein lipase (LPL), mainly expressed in the adipose tissue and muscle, is a key enzyme that regulates lipid metabolism via the hydrolysis of triglyceride in chylomicrons and very-low-density lipoproteins. Here, we aimed to investigate whether the suppression level of hepatic lipid accumulation via overexpression of LPL in mouse liver leads to improved metabolism. To overexpress LPL in the liver, we generated an LPL-expressing adenovirus (Ad) vector using an improved Ad vector that exhibited considerably lower hepatotoxicity (Ad-LPL). C57BL/6 mice were treated with Ad vectors and simultaneously fed a high-fat diet (HFD). Lipid droplet formation in the liver decreased in Ad-LPL-treated mice relative to that in control Ad vector-treated mice. Glucose tolerance and insulin resistance were remarkably improved in Ad-LPL-treated mice compared to those in control Ad vector-treated mice. The expression levels of fatty acid oxidation-related genes, such as peroxisome proliferator-activated receptor α, carnitine palmitoyltransferase 1, and acyl-CoA oxidase 1, were 1.7-2.0-fold higher in Ad-LPL-treated mouse livers than that in control Ad-vector-treated mouse livers. Furthermore, hepatic LPL overexpression partly maintained mitochondrial content in HFD-fed mice. These results indicate that LPL overexpression in the livers of HFD-fed mice attenuates the accumulation of lipid droplets in the liver and improves glucose metabolism. These findings may enable the development of new drugs to treat metabolic syndromes such as type 2 diabetes mellitus and non-alcoholic fatty liver disease.
No takes yet. Share an insight, caveat, or question.
Shimizu et al. (2022) studied High-fat diet-induced insulin resistance and hepatic lipid accumulation. Ad-LPL (liver-specific overexpression of lipoprotein lipase) vs. Ad-Luc (control vector) or PBS was evaluated on Hepatic lipid accumulation and glucose metabolism (glucose tolerance and insulin resistance) (p=<0.05). Liver-specific overexpression of lipoprotein lipase in high-fat diet-fed mice significantly attenuated hepatic lipid accumulation and improved glucose tolerance and insulin resistance.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: